T-Cell Vaccination for Multiple Sclerosis
The method works precisely: it suppresses only the immune cells attacking the nervous system and slows disease progression — without weakening overall immunity.
T-cell immunotherapy for multiple sclerosis
Multiple sclerosis is caused by an autoimmune process that destroys brain tissue: pro-inflammatory, myelin-reactive T-lymphocytes play a leading role. Standard treatments (hormones, cytostatics, interferons) exert a non-selective immunosuppressive effect and often lead to serious side effects.
The lymphocytic vaccination method stimulates immune reactions selectively directed at inactivating pathogenic idiotype-bearing T-lymphocytes. Their inactivation halts the development of the disease.
Substantial improvement in neurological status may be due to the intensification of nerve fiber remyelination processes — the nervous system of patients retains a certain regenerative potential.
How the treatment works
The duration of the course is about 2 months, depending on the body's individual response to immunotherapy.
Drug preparation
Autoaggressive T-lymphocytes are isolated from your blood to create an individualized preparation.
Drug preparation
Autoaggressive T-lymphocytes are isolated from your blood to create an individualized preparation.
Injection course
7–10 subcutaneous injections are administered over approximately 2 months.
Injection course
7–10 subcutaneous injections are administered over approximately 2 months.
Selective inactivation
Vaccination triggers anti-idiotypic reactions that suppress exactly the pathogenic T-lymphocytes without depressing overall immunity.
Selective inactivation
Vaccination triggers anti-idiotypic reactions that suppress exactly the pathogenic T-lymphocytes without depressing overall immunity.
Further treatment plan
Designed individually based on the dynamics of the patient's neurological status.
Further treatment plan
Designed individually based on the dynamics of the patient's neurological status.
Clinical Study Results
Efficacy is confirmed in both relapsing-remitting and secondary progressive (chronic) forms of the disease.
stable or improved
relapsing form (n = 32): progression in only 3 patients
without progression over 2 years
progressive form (n = 39) vs. 27% in control (n = 22)
showed neurological improvement
in the progressive form; zero cases in the control group
When the method is effective
In early and late stages
T-cell vaccination can be effective in both early and advanced stages of multiple sclerosis.
Regenerative potential
Inhibiting the underlying disease allows the nervous system's regenerative potential to be realized.
No general immunosuppression
The method is selective: it does not suppress general immunity and lacks the side effects typical of standard therapy.
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.